Atara Biotherapeutics, Inc. (LON:0HIY)
4.835
+0.205 (4.43%)
Feb 6, 2026, 5:04 PM GMT
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $3.45M USD in the quarter ending September 30, 2025, a decrease of -91.41%. This brings the company's revenue in the last twelve months to $151.93M, up 51.27% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$151.93M
Revenue Growth
+51.27%
P/S Ratio
0.23
Revenue / Employee
$4.00M
Employees
38
Market Cap
25.85M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Abingdon Health | 8.43M |
| Arecor Therapeutics | 5.06M |
| Renalytix | 2.19M |
| Fusion Antibodies | 1.60M |
Atara Biotherapeutics News
- 10 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - GlobeNewsWire
- 15 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - PRNewsWire
- 17 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA - GlobeNewsWire
- 23 days ago - Atara's Outlook As Ebvallo Hits Second FDA CRL - Benzinga
- 24 days ago - Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hold | ATRA Stock News - GuruFocus
- 25 days ago - Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - Nasdaq
- 25 days ago - Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
- 25 days ago - Monday Sector Laggards: Biotechnology, Credit Services & Lending Stocks - Nasdaq